foxo4-dri human trials results alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice FOXO4-DRI regulates endothelial cell senescence

daytime drowsiness, disturbances in REM sleep, insomnia, etc

Conclusion: AOD 9604 not only promotes weight loss, but also effectively prevents and reverses bone loss during the weight loss period, achieving a dual benefit of "weight loss+bone protection"

Table 1 provides a comprehensive overview of each studys design, cell line or animal species/strain use, route of administration (in vivo), exposure duration, dosage or concentration and main findings

Neither will specialized panels used by the Department of Transportation, military, or federal agencies

*None of the statements on this page have been evaluated by the Food and Drug Administration